Arcus Biosciences (RCUS) Tops Q3 EPS by 1c
Tweet
Share
E-mail
Get Alerts RCUS Hot Sheet
Join SI Premium – FREE
Arcus Biosciences (NYSE: RCUS) reported Q3 EPS of ($1.27), $0.01 better than the analyst estimate of ($1.28). Revenue for the quarter came in at $26 million versus the consensus estimate of $24.57 million.
For earnings history and earnings-related data on Arcus Biosciences (RCUS) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Lucid reports Q2 output, names new CFO and five other leaders
- Susquehanna Downgrades Greenbrier Companies (GBX) to Neutral
- Guardant Health (GH) PT Raised to $190 at BTIG, Top Pick
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
